Friday, April 30, 2010

Goshen Doctor on Time's 100 List.. Melanoma ..Jim Breitfeller

Goshen Doctor on Time's 100 List

TIME Magazine announced that Dr. Doug Schwartzentruber, Medical Director of Goshen Health System's Goshen Center for Cancer Care, has been named to the 2010 TIME 100, the magazine's annual list of the 100 most influential people in the world

He is being recognized for the strides he and Goshen Center for Cancer Care are making in cancer research.

"One of the first studies to prove vaccines might have a medical benefit against cancer, Schwartzentruber's study results found the new therapeutic cancer vaccine, given in combination with an existing melanoma treatment called Interleukin-2, doubled the response rate for tumor shrinkage as well as delayed the progression of cancer in patients with metastatic melanoma."


Goshen Doctor on Time's 100 List 2010

The reason I am brining this to your attention is that I have wrote to
Dr. Schwartzentruber.

The timing of the addition of IL-2 to the vaccine is crucial to the response outcome.

Just think what could be accomplished if Dr.Schwartzentruber timed the addition of the IL-2.

The Making of an Immune Response by Combinatorial Therapy Using Anti-CTLA-4 Blockade and Interleukin-2

Take Care,

Jimmy B


Tuesday, April 27, 2010

Melanoma: A model for testing new agents in combination therapies..Jim Breitfeller

Melanoma: A model for testing new agents in combination therapies

Email to Dr. Mario Sznol 4-27-2010

Dr. Sznol,

I just read your paper on test new agents in combination therapies. I would like you to take a look at a combination that I did as a stage IV Melanoma Patient under the care of Dr. John M. Kirkwood.

Melanoma: A model for testing new agents in combination therapies

It involves interferon alpha, DTIC + Patrin-2 , Anti-CTLA-4 blockade and HD interleukin-2. By doing these drugs in a systematic way, I was able to eradicate 40+ nodules in my lungs and others in the subcutaneous area of my back. Dr. Kirkwood thought I was a one off. Based on my 25 yrs. in the Kodak research labs as an analytical chemist, I was able to research why my treatment worked.

I would like to present it to you so you can expand on the knowledge and put it to practice.

Please don’t let it fall on deaf ears. We the patients need your help to think outside the box and push the Melanoma research to new frontiers.

Melanoma and The Magic Bullet (Monoclonal Antibodies)

Take Care,

Jimmy B


Sunday, April 25, 2010

Faltering Cancer Trials Melanoma.. Jim Breitfeller

Faltering Cancer Trials
Published: April 24, 2010

The government’s system for judging the clinical effectiveness of cancer treatments, recently found to be in “a state of crisis,” must be repaired.

Here is a recent article from the New York Times. Thanks to Ed a carepage friend and colleage for bringing this to my attention.


Faltering Cancer Trials

We need the Patients to unite and get the best therapy for their condition. This is not rocket science, it is biochemistry at it's best. We need Big Pharma(Bristol Myer Sqiubb, Novartis,Pfizer, Plexikkon, Hoffman La Roche and others) to step up to the plate and do what is ethical. Not just looking at their bottom line. Without patients/consumers, these drug companies would not exist.

Our future survival is in our hands. The cure is out there. We need the medical community to take notice.

Take Care,
Jimmy B


Friday, April 16, 2010

My CT scans have been Approved!! Melanoma ..Jim Breitfeller

My CT scans have been Approved!!
Posted 1 minute ago
My CT scans have been Approved!!!
The scans are scheduled for April 30th. 7:30 am.

I won't be able to release the data because it may Skew the ASCO data that will be released in June at the ASCO Annual Meeting.

God forbid we get the data early so that we, the patients, can make corrections to our path forward.

This is a Joke. ASCO holds back on data results until the start of their meeting and talks.

Why does ASCO embargo Clinical data that is positve before their annual Meeting? Melanoma The patients deserve better. Shame on ASCO!!!

Bristol-Myers Squibb announced the following pipeline highlights:
The company has data from its first phase 3 study (MDX-020) of ipilimumab, which had a primary endpoint of overall survival and was conducted in patients with previously-treated melanoma. Ipilimumab is a novel immuno-oncology compound in late-stage development.

The company has submitted study results for scientific presentation at the American Society of Clinical Oncology (ASCO) annual meeting in June. Management said it is in discussions with health authorities worldwide in planning for submitting biologics licensing applications (BLA) in this patient population.

The company also has data from a randomized phase 2 study of ipilimumab in non-small cell lung cancer that it also has submitted for presentation at ASCO this year. As a result of the study, the company is moving forward with a phase 3 study of ipilimumab in this indication.

Take Care,

Jimmy B

Thursday, April 15, 2010

Major Overhaul of NCI-Funded Cancer Trials Network Urged..Melanoma .Jim Breitfeller

Major Overhaul of NCI-Funded Cancer Trials Network Urged
By Alicia Ault
Elsevier Global Medical News
Breaking News
April 15, 2010 11:34 AM EDT

Saying that the cancer clinical trials system is in a state of crisis, an expert panel of the Institute of Medicine (IOM) called for an overhaul to speed up trial design and execution, incorporate scientific discoveries more rapidly, and create a structure to reimburse physicians and cover patients’ costs for participation in studies.

In a report issued Apr. 15, the 17-member panel said the backbone of the system, the National Cancer Institute-supported Clinical Trials Cooperative Group Program, has become cumbersome and inefficient. According to the report, it takes an average two years to design, approve, and start a trial. Only half of trials are ever completed. And, while knowledge is exponentially increasing, the groups’ funding has decreased by 20% over the last 8 years.

Moreover, enrollment in trials is abysmal. The American Cancer Society estimates that only 5% of adults with cancer participate.

“Cooperative group studies have steadily improved the care of cancer patients for more than 50 years, but the program is at a breaking point,” said the IOM panel’s chairman, Dr. John Mendelsohn, president of the University of Texas M.D. Anderson Cancer Center in Houston.

“The program urgently needs changes across the board, if it is going to continue producing the kind of studies necessary to answer crucial and fundamental questions about how to successfully treat and prevent cancer, which can't be answered through other means,” he said.

The American Society of Clinical Oncologists (ASCO) applauded the IOM panel’s recommendations. “The Cooperative Clinical Research Program is the jewel in our nation’s cancer research system, and is critical to advancing progress against the disease,” said Dr. Richard L. Schilsky, immediate past president of ASCO, in a statement.

The Cooperative Group Program, which is supported by the National Cancer Institute (NCI), comprises 10 groups that incorporate 3,100 institutions and 14,000 investigators. Some 25,000 patients participate in cooperative trials each year.

The IOM says that the groups have made important contributions over the half-century they have been in existence. For instance, largely as a result of findings from cooperative trials, pediatric cancer survival rates rose from 10% in the 1950s to 80% now, said the report.

Because the program does have the potential to be more efficient and effective, “it is imperative to preserve and strengthen the unique capabilities of the Cooperative Group Program as a vital component in NCI’s translational continuum,” wrote the panelists in the report.

It will be an uphill battle. Currently, funding for the groups makes up only 3% of the NCI’s budget.

Dr. Schilsky said that “the system is being starved of funding.” In real dollars, “the program receives less funding today than it did a decade ago,” he noted.

“ASCO calls on NCI to double its support for cooperative clinical research within five years,” said Dr. Schilsky, a professor of medicine and section chief, hematology/oncology at the University of Chicago Medical Center, who also served on the panel.

The IOM panel called for increased funding, but also urged changes that could be made without new money. It recommended an evaluation of the necessity and contributions of each group, and a shift by the NCI from oversight to pure facilitation of trials. The groups need to move beyond cooperation to “integration,” said the report. That would include a consolidation of some front office and back office operations of the groups and improved collaboration among all the stakeholders.

The ability to recruit, train, and retain enough clinical investigators is also crucial to the rebuilding of the trial system, said the IOM panel. It recommended that health insurers, Medicare, and federal and state health programs cooperate to establish consistent payment policies to cover all patient care costs in a trial, except for the drugs, devices, or diagnostics, which should continue to be paid for by the manufacturers.

Such policies might act as an incentive for patients to participate in trials, said the panel.

The experts also urged the American Medical Association to create new current procedural terminology (CPT) codes that would create a payment pathway for offering, enrolling, managing, and following a patient through a clinical trial. The new codes would reflect the additional time that physicians put in to getting patients into a trial, and for managing potential adverse events.

And, they would likely be a powerful incentive for physicians to consider putting more of their patients in studies, said the panel.

Physicians, indeed, are not happy about reimbursement. An ASCO survey released Apr. 15 showed that one-third of Cooperative Group Sites said they planned to limit participation in those trials due to inadequate per-case reimbursement. Almost 40% of those who were going to limit cooperative studies said they would instead increase their participation in industry-sponsored trials.


Take Care,

Jimmy B

Wednesday, April 14, 2010

Applying Dosing Schedules to the Protocols of Combo Therapy, Optimize the clinical outcome 4-14-2010 Note to Rosenberg Melanoma Jim Breitfeller

Applying dosing schedules to the clinical protocols of combinatorial therapy, we can optimize the clinical outcome 4-14-2010 Note to Dr. Rosenberg
In 1986, a clinical protocol for the treatment of advanced malignant melanoma with
the newly discovered class of immune cells called TIL was initiated at the National Institutes of Health (NIH). These lymphocytes are T cells that are isolated directly from the tumor and that are then grown to large numbers in tissue culture in the presence of the T cell growth factor interleukin-2 (IL2). After expansion in culture several thousand times, approximately 2 X 10" TIL are given to the patient intravenously in addition to high doses of IL-2 in several days of treatment. Even in those patients who did not respond to all other therapy (including treatment with IL-2 alone), 35 to 40% of patients responded to this protocol.

The large-scale tissue culture and the large numbers of cells and IL-2 that are given to a patient make this procedure expensive and clinically difficult. Furthermore, 60 to 65% of patients fail to respond to this treatment, and even those who do respond will often fail after 6 to 12 months. It is likely that only a subset of the heterologous population of cells administered to a patient are effective in killing cancer cells in vivo.

That was then (1986) and this is now 2009. Dr. Rosenberg and colleagues have optimized the protocol to generate a response rate of 72% using lymphodepletion prior to Adaptive Cell Therapy.

It cannot be certain that the TIL subsets preferentially recovered from the tumor biopsy corresponded to those that mediated complete elimination of tumor in this patient.

Recently, a patient that went down to NIH and did the ACT therapy had a response only where the cells came from (lungs). The other tumors continued to progress.

Are the TILs tumor specific based on where the cells were obtained during biopsy? Does this mean the other tumors mutated or are they missing some receptor or MHC I or II at the tumor surface?

Adoptive Cell Transfer.. 57 days after transfer. CD8+ T-cell (CTLs) at the Maximum Propagation

A tumor lesion excised from patient 9 before nonmyeloablating chemotherapy ("pretreatment") exhibited scant CD8+ cells (left), strong stromal cell staining but weak staining of tumor cells with antibody to MHC class I (center), and sporadic cell staining with an antibody to MHC class II (probably tumor macrophages) but minimal staining of tumor cells (right). In contrast, a sample resected 57 days after cell transfer ("post treatment") exhibited a dense, diffuse CD8+ infiltrate and ubiquitous expression of both MHC class I and class II molecules in tumor cells.

Source: Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Originally published in Science Express on 19 September 2002
Science 25 October 2002:
Vol. 298. no. 5594, pp. 850 - 854
DOI: 10.1126/science.1076514

Patients undergoing Anti-CTLA-4 Blockadge. Week7 = Day 49 maximum ALC.. CD8+ T-cell (CTLs)

Source: Dr. Jedd Wolchok

What I am trying to show is the growth curves for the various T-cells subsets with data from in vivo to back up the above graphic. With that in mind, we now have a better understanding on the growth patterns of these cells. By applying dosing schedules to the clinical protocols of combinatorial therapy, we can optimize the clinical outcome

Take Care,

Jimmy B

Sunday, April 11, 2010

'Cure' is found for skin cancer, claim scientists..Melanoma ..Jim Breitfeller

'Cure' is found for skin cancer, claim scientists

Scientists believe that they have found a cure for skin cancer.

Published: 12:25AM BST 11 Apr 2010

A vaccine being tested in the UK has helped been shown to help some patients fully recover from melanoma, even in its advanced stages.

It attacks tumour cells, leaving healthy cells undamaged and carries agents that boost the body's response to skin cancer.

Dr Howard Kaufman, of Chicago's Rush University Medical Centre, said: "Our study shows we may have a cure for some advanced melanoma patients and a drug which has real benefits for others.

"This will save thousands of lives a year."

Over the past 25 years, rates of melanoma in Britain have risen faster than any other common cancer and 2,000 die from the disease every year.

A study of 50 patients with advanced melanoma who had been given no more than nine months to live found that 16 per cent of them recovered completely with the vaccine. They have been disease-free for more than four years.

Another 28 per cent saw the size of their tumours more than halved.

It is hoped the licensing will be "fast-tracked" and it will be on the market within five years.

Melanoma is now the most common cancer in young adults aged 15 to 34, with 10,41 new cases diagnosed every year in the UK.


The Company’s lead product, OncoVEXGM-CSF is a first in class oncolytic vaccine. OncoVEXGM-CSF is currently being evaluated in a Phase 3 multi-national study in metastatic melanoma and a Phase 3 study in head and neck cancer is scheduled to commence in the second half of 2010. BioVex believes OncoVEXGM-CSF has the potential to become a leading standard of care in the treatment of many solid tumors based on the strength of clinical data so far generated coupled with the relatively benign side effect profile noted to date.

The Company has recently also commenced clinical testing in the UK with its vaccine candidate for the prevention and potentially the treatment of genital herpes.


OncoVEX Trials

Check them out!!!!!
For more information about participating in OPTiM call 888-990-3399 or email
Local and Distant Immunity Induced by Intralesional Vaccination
with an Oncolytic Herpes Virus Encoding GM-CSF in Patients
with Stage IIIc and IV Melanoma

Take Care,

Jimmy B

Friday, April 9, 2010

Improve Survival from Advanced Melanoma..The Time Is Now!! Jim Breitfeller

"• Drug development efforts focusing on rare and understudied diseases such as
melanoma face unique challenges. Addressing the rising incidence and unique
biology of human melanoma will require a well-defined process to access and provide
input to existing NCI drug development programs such as the Cancer Therapy
Evaluation Program (CTEP) and the Rapid Access to Intervention Development
(RAID) program. The procedures followed by CTEP for identifying new agents for
evaluation and introducing them into clinical trials should be streamlined, and
interactions between CTEP and RAID should be expedited. Currently, the
Investigational Drug Steering Committee (IDSC) is designed to provide NCI with
broad external scientific and clinical input for the design and prioritization of phase I
and phase II trials with agents. IDSC membership has included principal
investigators, representatives from the NCI Cooperative Groups, NCI staff members,
and additional representatives as ad hoc members for consideration of specific agents.

• To facilitate rational clinical trials of therapies for advanced melanoma, researchers
need improved access to new drugs and orphan drugs. Testing of combinations of
drugs from multiple sources, including pharmaceutical companies and academia, will
accelerate progress in melanoma research. This is currently hindered by legal liability
and intellectual property issues. Regulatory support, and the additional funding
required, should be provided to facilitate access to promising drugs for preclinical and
clinical studies relevant to melanoma, even if their application is limited to this
disease, in order to address legal and IP issues. Drug companies should be
indemnified against the risks of allowing their drugs to be combined in innovative
strategies to encourage participation in melanoma clinical trials.

• Lost-opportunity drugs should be identified, and funds should be devoted to
production, validation, and quality control for drugs that private industry is unwilling
or unable to develop due to the perception that the market is limited. This is
particularly relevant when the investigational agent is not expected to have single
agent activity, but could be essential as an adjuvant to a vaccine or supplement one of
the important, existing immunologic approaches in melanoma.

• The melanoma research community needs dedicated support for the efficient study of
scientific opportunities within timelines expected in the more common tumors.
Funding for innovative new trials, especially those using agents from CTEP or
prepared by the RAID program, should be increased. This can be accomplished by
leveraging existing programs and creating partnerships.

• Biological discoveries in trials of patients with advanced disease may inform the
research in premalignant and early-stage disease, as well as predict which patients will
respond to immunologic therapies such as interleukin, interferon, T-cell antibodies, or
other signaling pathways. The government has a unique opportunity to stimulate
scientific research simultaneously with federally-supported treatment trials. Funding
should be designated for bench-to-bedside translational research through those clinical
trials that have the greatest potential to improve melanoma survival.
• A high-priority should be to enhance infrastructure that supports clinical trials in rare
diseases. Rare diseases require a focused national accrual effort for early drug
development trials in addition to large, randomized Phase III trials. Single-institution
funding is not sufficient to coordinate a national infrastructure. Existing structures
such as the NCI Cancer Trials Support Unit (CTSU) could provide regulatory
coordination and access on a national scale for Phase II trials, allowing the pace of
scientific inquiry to approach that of trials in common tumors."

Source: Final Melanoma Action Plan of 2007 NCI

Final Melanoma Action Plan of 2007 NCI

“You Can’t Start a Fire Without a Spark!!”

We need everyone to work together and drop the GREED.

Shared files

Take Care,

Jimmy B

Greetings to One and All

This Blog is dedicated My Brother Kenny B. who passed away in the late 1970's with Cancer before the Internet.

It was he, who showed me How to live and give back. He was wise beyond his years.

Kenny B

Jimmy and Dee

Carepage: Jimmybreitfeller
Jimmy Breitfeller

My Profile as of 2009

My photo
Last July (2005)I was riding my bicycle to work at the Eastman Kodak Research Labs about 3 miles from home. I was wearing a knapsack to carry my things to and from the labs. I started noticing an ache on my back. So I decide to go to the dermatologist. To make the long story short, it was cancer. I knew from my research that I would be needing adjuvant therapy. So I started communicating with Sloan Kettering, University of Pittsburgh Cancer Center, and a couple of others including the Wilmot Cancer Center at Strong. I realized that by telling my story, I might help someone else out there in a similar situation. So to all who are linked by diagnosis or by relation to someone with melanoma, I wish you well. Stay positive, read as much as you can (information helps to eliminate the fear associated with the unknown), and live for today, as no one can predict what tomorrow may bring. Jimmy B. posted 12/15/08


The information contained within this Blog is not meant to replace the examination or advice of your Oncologist or Medical Team. The educational material that is covered here or Linked to, does not cover every detail of each disorder discussed.

Only your physician/Oncologist can make medical decisions and treatment plans that are appropriate for you. But, An Educated Consumer is a Smart consumer.

As Dr. Casey Culberson Said:

"The BEST melanoma patient is an ACTIVE PARTICIPANT in his or her treatment

Melanoma and the “Magic Bullet” (Monoclonal Antibodies)

Just to let you know I posted the first draft of the Melanoma and the “Magic Bullet” (Monoclonal Antibodies). on Melanoma Missionary In the Shared File Section. you can download it for 19.95 (Only kidding) it is Free for the taking.

It is 33 pages long and may help you in your quest for the Yellow Brick Broad. Just to let you know it is only the first draft. Revisions are sure to come. I wanted to get it to the people that need it the most, the Melanoma Patients.


So, where does Interluekin-2 (IL-2) come into play? According to Byung-Scok et al and recent reports, IL-2 is not needed for developmental CD4+ CD25+ Treg cells in the thymus but does play an important role in the maintenance and function in the peripheral.18 Peripheral is defines as secondary system outside the bone marrow and thymus. It entails the site of antigen, immune system interaction. IL-2 is required for the peripheral generation of Tregs based Abbas’s and colleagues research.19

IL-2 prevents the spontaneous apoptosis of the CD4+ CD25+ Treg cells. It has been reported that patients with multiple advance-stage tumors have elevated levels of Tregs within the tumor microenviroment.20 Interluekin-2 is the survival factor for CD4+ CD25+ Treg cells.21 If the addition of IL-2 is on or before the maximum propagation of the CD4+ T cells, the Tregs population can increase 5-fold in a 96 hour period based on certain growth mediums.

By controlling the addition of the endogenous IL-2, one has a knob to turn and can lead to the control of the expansion of the Tregs. When you combined this control with the anti-CTLA-4 blockage, you can shift the balance of the immune response.

Now here is the catch. The maintenance and function of the CD8+ T-cells require CD4+ cells which secrete IL-2. So we don’t want to deplete the CD4+ cells, we want to control the expansion of the Tregs which are a subset of the CD4+ cells. It has been postulated by some researchers that the Anti-CTLA-4 blockage also suppresses the Treg function in a different mechanism. By using IL-2 as the rate limiting factor, we can suppress the CD4+ CD25+ Treg cell expansion by controlling the concentration and timing of the Inerluekin-2 at the tumor microenvironment.

The Interluekin-2 plays another role in this Melanoma Maze. In a study by Janas et al, Il-2 increases the expressions of the perforin and granzyme A, B and C genes in the CD8+ T-cells. This increase expression causes the CD8+ T-cells to mature into Cytoxic T Lymphocytes (CTLs). The exogenous IL-2 is required for the granzyme proteins. As stated previously, CTLs have cytoplasmic granules that contain the proteins perforin and granzymes. A dozen or more perforin molecules insert themselves into the plasma membrane of target cells forming a pore that enables granzymes to enter the cell. Once in the tumor cell, these enzymes are able to breakup (lyse) the cell and destroy it. This is the beginning of the end for the cancer cells. The tumors begin to shrink and the rest is history,

On the other hand, prolong therapy with Il-2 can result in causing apoptotic death of the tumor- specific CD8+ T-cells.23

Clearly in a clinical setting, timing, dose, and exposure to these drugs play a major roll in the immunotherapy, and can have dramatic effects on the outcome.

All it takes is that one magic bullet to start the immune reaction..

Melanoma And The Magic Bullet (Monoclonal Antibodies)

Public Service Announcement

A call for Melanoma Patients by Dr. Steven A Rosenberg

"We continue to see a high rate of clinical responses in our cell transfer immunotherapy treatments for patients with metastatic melanoma", Dr. Rosenberg said.

"We are actively seeking patients for these trials and any note of that on a patient-directed web site would be appreciated."

If you would like to apply for his trials, here is the website and information.

Dr. Rosenberg's information

Dr. Rosenberg's Clinical Trials

For the Warriors

The Melanoma Research Alliance has partnered with Bruce Springsteen, the E Street Band, and the Federici family to alleviate suffering and death from melanoma. Please view Bruce Springsteen’s public service announcement inspired by Danny Federici. Danny was the E Street Band’s organist and keyboard player. He died on April 17, 2008 at Memorial Sloan-Kettering Cancer Center in New York City after a three year battle with melanoma.

Source Fastcures blog

Join the Relay for Life!!!


Dear Family and Friends,

I’ve decided to take a stand and fight back against cancer by participating in the American Cancer Society Relay For Life® event right here in my community! Please support me in this important cause by making a secure, tax-deductible donation online using the link below.

To donate on line now, click here to visit my personal page.
Jimmy B AKA Melanoma_Missionary

Relay For Life® is a life-changing event that brings together more than 3.5 million people worldwide to:

CELEBRATE the lives of those who have battled cancer. The strength of survivors inspires others to continue to fight.

REMEMBER loved ones lost to the disease. At Relay, people who have walked alongside people battling cancer can grieve and find healing.

FIGHT BACK. We Relay because we have been touched by cancer and desperately want to put an end to the disease.

Whatever you can give will help - it all adds up! I greatly appreciate your support and will keep you posted on my progress.

Keep the Fire Burning!!!



Jimmy Breitfeller
Turn off Music before you "Click to Play"
Signs of Melanoma Carcinoma Skin Cancer

How Skin Cancer Develops by " : Dermatology"

Call for Patients with Unresectable Liver Metastases Due to Melanoma

Delcath Systems Granted Orphan-Drug Designations for Cutaneous and Ocular Melanoma

Delcath is actively enrolling patients in a Phase III clinical trial testing its proprietary drug delivery system, known as Percutaneous Hepatic Perfusion (“PHP”), with melphalan for the treatment of ocular and cutaneous melanoma metastatic to the liver.

This NCI-led trial is enrolling patients at leading cancer centers throughout the United States. Commenting on these orphan-drug designations, Richard L. Taney, President and CEO of Delcath, stated, “These favorable designations are important steps in our efforts to secure Delcath’s commercial position upon conclusion of our pivotal Phase III trial for metastatic melanoma. We remain steadfast in our commitment to become the leader in the regional treatment of liver cancers and we continue to enroll patients in this study, and advance our technology and the promise that it offers to patients with these deadly forms of melanoma and other cancers of the liver, all with limited treatment options.”

Orphan drug designation, when granted by the FDA’s Office of Orphan Products Development, allows for up to seven years of market exclusivity upon FDA approval, as well as clinical study incentives, study design assistance, waivers of certain FDA user fees, and potential tax credits.

Current Trial Centers

Phase I Study of Hepatic Arterial Melphalan Infusion and Hepatic Venous Hemofiltration Using
Percutaneously Placed Catheters in Patients With Unresectable Hepatic Malignancies

James F. Pingpank, Jr., MD, FACS
Associate Professor of Surgery
Division of Surgical Oncology
Suite 406, UPMC Cancer Pavillion
5150 Centre Avenue
Pittsburgh, PA 15232
412-692-2852 (Office)
412-692-2520 (Fax)

Blog Archive

Call For Melanoma Patients!!!!

Call For Melanoma Patients!!!!

Dr. Rosenberg Has a New Clinical Trial.

Our latest treatment has a 72% objective response rate with 36% complete responses.

We are currently recruiting patients for our latest trial.

Is there some way to post this “Call for Patients” on the web site?

Steve Rosenberg

Dr. Rosenberg's Clinical Trials

(For a copy of the research paper.. see My Shared files)

The news headlines shown above for Melanoma / Skin Cancer are provided courtesy of Medical News Today.